Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gene amplifications in osteosarcoma-CGH microarray analysis.

Jassu Atiye1, Maija Wolf, Sippy Kaur

  • 1Departments of Pathology and Medical Genetics, Haartman Institute and HUSLAB, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland.

Genes, Chromosomes & Cancer
|November 13, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Microinvasive, off-pump, transventricular neochordae implantation in recurrent mitral valve regurgitation after open heart surgical repair.

The Journal of thoracic and cardiovascular surgery·2026
Same author

Evaluation of Radiotherapy Dose in Secondary Breast Angiosarcoma: Implications for Pathogenesis.

Anticancer research·2026
Same author

Reply to: Mifamurtide in Nonmetastatic High-Grade Osteosarcoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

VEGF Signaling Pathway Germline Polymorphisms as Prognostic Pharmacogenetic Biomarkers in Localized High-Grade Osteosarcoma Patients from the GEIS-33 Protocol.

Pharmaceuticals (Basel, Switzerland)·2025
Same author

Establishment and Characterization of OS-MET-R-092: A Novel Patient-Derived Cell Culture from an Osteosarcoma Bone Metastasis.

International journal of molecular sciences·2025
Same author

SMARCAL1 is a new osteosarcoma predisposition gene.

Journal of the National Cancer Institute·2025
Same journal

Biphenotypic Sinonasal Sarcoma With a Novel PAX3::MAML2 Fusion.

Genes, chromosomes & cancer·2026
Same journal

An Affordable and Efficient In-House Approach for Detecting Gene Fusions in Bone and Soft Tissue Tumors Using a Custom Capture Panel and Nanopore Sequencing.

Genes, chromosomes & cancer·2026
Same journal

PKMYT1 in Cancer: Beyond Cell Cycle Checkpoints to Context-Dependent Therapeutic Vulnerability.

Genes, chromosomes & cancer·2026
Same journal

Associations of Dietary Intake Traits and Aging Indicators With Colorectal Cancer: A Mendelian Randomization Study.

Genes, chromosomes & cancer·2026
Same journal

Primary Tumor-Associated Loss of the Y Chromosome and Clinical Outcome in Metastatic Colorectal Cancer.

Genes, chromosomes & cancer·2026
Same journal

Cytogenetic and Molecular Analysis of a "Double-Hit" RUNX1 Including a RUNX1 p.Trp279* and a Cryptic Novel t(6;21)(q25;q22)/RUNX1::ARID1B in Acute Myeloid Leukemia.

Genes, chromosomes & cancer·2026
See all related articles

Genomic analysis of osteosarcoma revealed widespread gene copy number alterations. Novel amplifications were identified, providing new targets like TOM1L2 and CYP27B1 for understanding this bone cancer.

Area of Science:

  • Genomics
  • Cancer Biology
  • Molecular Oncology

Background:

  • Osteosarcoma genomic alterations remain largely unknown.
  • Understanding these alterations is crucial for developing targeted therapies.

Purpose of the Study:

  • To identify genomic alterations in osteosarcoma.
  • To characterize novel amplicons and potential therapeutic targets.

Main Methods:

  • Genome-wide high-resolution gene copy number analysis.
  • Comparative genomic hybridization (CGH) on cDNA microarrays.
  • Analysis of 22 osteosarcoma samples.

Main Results:

  • Nineteen of 22 cases showed large gene amplifications (>1 Mb).
  • Novel amplicons identified at 14q11, 17q25, and 22q11-q13.

Related Experiment Videos

  • Amplification of 12q occurred in 36% of cases, more frequent than previously reported.
  • TOM1L2 and CYP27B1 implicated as novel targets for 17p and 12q amplicons.

    • Conclusions:

    • Genomic copy number changes are prevalent in osteosarcoma.
    • Identified novel amplicons and amplified genes provide insights into osteosarcoma pathogenesis.
    • TOM1L2 and CYP27B1 are potential therapeutic targets for osteosarcoma.